The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study
Nab-paclitaxel is used in patients with advanced breast cancer. In this real-world, non-interventional study, prognosis was favorable and safety profile manageable, which is comparable to previous clinical trials and real-world studies.
Authors
- Matthias Ruebner (ORCID: https://orcid.org/0000-0002-2408-1138)
- Marion van Mackelenbergh (ORCID: https://orcid.org/0000-0002-1084-5897)
- Frederik Marmé (ORCID: https://orcid.org/0000-0002-6591-3367)
- Andreas D. Hartkopf (ORCID: https://orcid.org/0000-0003-1227-1118)
- Thomas Spall
- D. Wallwiener (ORCID: https://orcid.org/0000-0002-4635-5283)
- Lothar Häberle (ORCID: https://orcid.org/0000-0003-4019-9328)
- Erik Belleville
- Sara Yvonne Brucker (ORCID: https://orcid.org/0000-0001-8588-1094)
- Marc Thill (ORCID: https://orcid.org/0000-0002-8800-8044)
- Sabrina Uhrig
- Hans Tesch (ORCID: https://orcid.org/0000-0001-7839-4917)
- Anna‐Katharin Theuser (ORCID: https://orcid.org/0000-0003-2860-3500)
- Tanja Fehm (ORCID: https://orcid.org/0000-0002-4926-0108)
- Andreas Schneeweiß (ORCID: https://orcid.org/0000-0002-2429-4512)
- Peter A. Fasching
- Tjoung‐Won Park‐Simon
- Oliver Tomé
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Medizinische Hochschule Hannover (DE)
- Universitätsklinikum Erlangen (DE)
- Cardiovascular Center Bethanien (DE)
- Düsseldorf University Hospital (DE)
- Institut für Frauengesundheit (DE)
- National Center for Tumor Diseases (DE)
- University Hospital Schleswig-Holstein (DE)
- St. Vincentius-Kliniken (DE)
- University Children's Hospital Tübingen (DE)
- Agaplesion Markus Hospital (DE)
- Comprehensive Cancer Center Erlangen (DE)
- University Medical Centre Mannheim (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1007/s00432-025-06246-2
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Amgen
- Pfizer
- Teva Pharmaceutical Industries
- Celgene
- Servier
- Universitätsklinikum Erlangen
- Daiichi Sankyo Europe